Literature DB >> 17298945

The conserved CPH domains of Cul7 and PARC are protein-protein interaction modules that bind the tetramerization domain of p53.

Lilia Kaustov1, Jonathan Lukin, Alexander Lemak, Shili Duan, Melissa Ho, Ryan Doherty, Linda Z Penn, Cheryl H Arrowsmith.   

Abstract

Cul7 is a member of the Cullin Ring Ligase (CRL) family and is required for normal mouse development and cellular proliferation. Recently, a region of Cul7 that is highly conserved in the p53-associated, Parkin-like cytoplasmic protein PARC, was shown to bind p53 directly. Here we identify the CPH domains (conserved domain within Cul7, PARC, and HERC2 proteins) of both Cul7 and PARC as p53 interaction domains using size exclusion chromatography and NMR spectroscopy. We present the first structure of the evolutionarily conserved CPH domain and provide novel insight into the Cul7-p53 interaction. The NMR structure of the Cul7-CPH domain reveals a fold similar to peptide interaction modules such as the SH3, Tudor, and KOW domains. The p53 interaction surface of both Cul7 and PARC CPH domains was mapped to a conserved surface distinct from the analogous peptide-binding regions of SH3, KOW, and Tudor domains, suggesting a novel mode of interaction. The CPH domain interaction surface of p53 resides in the tetramerization domain and is formed by residues contributed by at least two subunits.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17298945     DOI: 10.1074/jbc.M611297200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

Review 1.  Inhibition of NEDD8-conjugation pathway by novel molecules: potential approaches to anticancer therapy.

Authors:  Tomoaki Tanaka; Tatsuya Nakatani; Tetsu Kamitani
Journal:  Mol Oncol       Date:  2012-01-21       Impact factor: 6.603

2.  Sequence specific resonance assignment via Multicanonical Monte Carlo search using an ABACUS approach.

Authors:  Alexander Lemak; Carlos A Steren; Cheryl H Arrowsmith; Miguel Llinás
Journal:  J Biomol NMR       Date:  2008-05-06       Impact factor: 2.835

3.  p53 is an important regulator of CCL2 gene expression.

Authors:  X Tang; M Asano; A O'Reilly; A Farquhar; Y Yang; S Amar
Journal:  Curr Mol Med       Date:  2012-09       Impact factor: 2.222

4.  The E3 ubiquitin protein ligase HERC2 modulates the activity of tumor protein p53 by regulating its oligomerization.

Authors:  Monica Cubillos-Rojas; Fabiola Amair-Pinedo; Roser Peiró-Jordán; Ramon Bartrons; Francesc Ventura; Jose Luis Rosa
Journal:  J Biol Chem       Date:  2014-04-09       Impact factor: 5.157

5.  Cytoplasmic CUL9/PARC ubiquitin ligase is a tumor suppressor and promotes p53-dependent apoptosis.

Authors:  Xin-Hai Pei; Feng Bai; Zhijun Li; Matthew D Smith; Gabrielle Whitewolf; Ran Jin; Yue Xiong
Journal:  Cancer Res       Date:  2011-04-12       Impact factor: 12.701

6.  Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924.

Authors:  Hua Liao; Xiaozhen J Liu; Jonathan L Blank; David C Bouck; Hugues Bernard; Khristofer Garcia; Eric S Lightcap
Journal:  Mol Cell Proteomics       Date:  2011-08-26       Impact factor: 5.911

7.  Special AT-rich binding protein-2 (SATB2) differentially affects disease-causing p63 mutant proteins.

Authors:  Jacky Chung; R Ian Grant; David R Kaplan; Meredith S Irwin
Journal:  J Biol Chem       Date:  2011-09-29       Impact factor: 5.157

8.  p53 suppresses CCL2-induced subcutaneous tumor xenograft.

Authors:  Xiaoren Tang; Salomon Amar
Journal:  Tumour Biol       Date:  2014-12-11

9.  The HECTD3 E3 ubiquitin ligase suppresses cisplatin-induced apoptosis via stabilizing MALT1.

Authors:  Yi Li; Xi Chen; Zehua Wang; Dong Zhao; Hui Chen; Wenlin Chen; Zhongmei Zhou; Junran Zhang; Jing Zhang; Hongmin Li; Ceshi Chen
Journal:  Neoplasia       Date:  2013-01       Impact factor: 5.715

10.  The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation.

Authors:  Xinsong Xu; Antonio Sarikas; Dora C Dias-Santagata; Georgia Dolios; Pascal J Lafontant; Shih-Chong Tsai; Wuqiang Zhu; Hidehiro Nakajima; Hisako O Nakajima; Loren J Field; Rong Wang; Zhen-Qiang Pan
Journal:  Mol Cell       Date:  2008-05-23       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.